Steve Carchedi, President and CEO of Apexian Pharmaceuticals, is scheduled to speak March 1 at Drexel University’s Healthcare Guest Lecture Series in Philadelphia.
“Drexel has a wonderful history of developing leaders in the healthcare industry,” Carchedi said. “We are honored to partner with faculty at Drexel to attract talent to pursue development of life-saving medicines, like our lead molecule, APX3330, that is ready to advance into the clinic. Hopefully, some of these students will be leading the effort for future breakthrough medicines.”
Apexian Pharmaceuticals, formerly ApeX Therapeutics, recently announced acceptance by the U.S. Food and Drug Administration of an Investigational New Drug Application to evaluate the tolerability and anti-tumor effects of APX3330, a small molecule in development to treat late stage cancer. The company licenses IU-discovered research through Indiana University Research and Technology Corp.
A news release about Carchedi and Drexel University’s Healthcare Guest Lecture Series is available here.
Leave a Reply